Hillsdale Investment Management Inc. Lowers Holdings in Collegium Pharmaceutical, Inc. $COLL

Hillsdale Investment Management Inc. decreased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 10.6% in the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 184,600 shares of the specialty pharmaceutical company’s stock after selling 22,000 shares during the period. Hillsdale Investment Management Inc.’s holdings in Collegium Pharmaceutical were worth $6,105,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the business. Group One Trading LLC bought a new stake in Collegium Pharmaceutical during the 4th quarter valued at approximately $28,000. Caitong International Asset Management Co. Ltd boosted its stake in Collegium Pharmaceutical by 205.3% in the 4th quarter. Caitong International Asset Management Co. Ltd now owns 635 shares of the specialty pharmaceutical company’s stock worth $29,000 after purchasing an additional 427 shares during the period. Kemnay Advisory Services Inc. bought a new position in Collegium Pharmaceutical in the 4th quarter worth approximately $61,000. Mirae Asset Global Investments Co. Ltd. grew its holdings in Collegium Pharmaceutical by 26.1% during the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 1,536 shares of the specialty pharmaceutical company’s stock valued at $71,000 after buying an additional 318 shares in the last quarter. Finally, EverSource Wealth Advisors LLC grew its holdings in Collegium Pharmaceutical by 744.9% during the 2nd quarter. EverSource Wealth Advisors LLC now owns 2,484 shares of the specialty pharmaceutical company’s stock valued at $73,000 after buying an additional 2,190 shares in the last quarter.

Collegium Pharmaceutical Stock Performance

NASDAQ COLL opened at $35.02 on Wednesday. The company has a debt-to-equity ratio of 2.47, a current ratio of 1.71 and a quick ratio of 1.62. Collegium Pharmaceutical, Inc. has a 1-year low of $29.19 and a 1-year high of $50.79. The business has a 50 day simple moving average of $34.71 and a two-hundred day simple moving average of $38.54. The stock has a market capitalization of $1.14 billion, a PE ratio of 17.17 and a beta of 0.73.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its quarterly earnings data on Thursday, May 7th. The specialty pharmaceutical company reported $1.76 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.52 by $0.24. The business had revenue of $193.52 million for the quarter, compared to analysts’ expectations of $184.47 million. Collegium Pharmaceutical had a return on equity of 95.18% and a net margin of 9.41%.The company’s revenue for the quarter was up 8.9% on a year-over-year basis. During the same period in the prior year, the firm earned $1.49 EPS. On average, research analysts predict that Collegium Pharmaceutical, Inc. will post 6.76 EPS for the current fiscal year.

Wall Street Analyst Weigh In

COLL has been the topic of several research analyst reports. Truist Financial raised shares of Collegium Pharmaceutical to a “strong-buy” rating in a report on Monday, June 15th. Zacks Research raised shares of Collegium Pharmaceutical from a “hold” rating to a “strong-buy” rating in a research note on Monday, June 29th. Weiss Ratings reaffirmed a “hold (c)” rating on shares of Collegium Pharmaceutical in a research note on Monday, July 6th. Wall Street Zen upgraded shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 9th. Finally, HC Wainwright reiterated a “buy” rating and issued a $60.00 price target on shares of Collegium Pharmaceutical in a research note on Friday, March 20th. Two equities research analysts have rated the stock with a Strong Buy rating, three have issued a Buy rating and one has given a Hold rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Buy” and an average price target of $57.50.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc is a specialty pharmaceutical company focused on the development, manufacture and commercialization of products for pain management and opioid dependence. The company’s core expertise lies in its DETERx microsphere technology, a platform designed to provide extended-release delivery of active pharmaceutical ingredients while deterring manipulation for unintended routes of abuse.

The company’s principal marketed products include Xtampza® ER (extended-release oxycodone), which received approval from the U.S.